Antoine Courgeon works within the Life Sciences group of BOEHMERT & BOEHMERT. He has notable experience managing large, complex portfolios of patent families in regenerative medicine, cell therapy, antisense therapeutics, and more extensively in immunology and vaccine technologies. He has advised executive teams of pharmaceutical companies on crucial patent protection and exclusivity for blockbuster biologics and vaccines. Antoine Courgeon has conducted IP due diligence on strategic deals and frequently provided validity and freedom-to-operate opinions to evaluate complex patent portfolio for multi-million R&D investments. He has experience in the licensing business and provided sophisticated counselling to business development and R&D to protect key commercial assets and platform technologies.
T +49 (30) 23 60 76 70
F 49 (30) 23 60 76 721
Before joining BOEHMERT & BOEHMERT in 2020, Antoine Courgeon spent most of his career working for blue-chip pharmaceutical companies such as Novartis, GlaxoSmithKline and Pfizer. 15 years’ experience in the biopharma and vaccine industry has given him a special attention to the clients’ business strategy and priorities. Currently, he is engaged with enforcement and protection of IP rights, including initial case analysis, ongoing case strategy, and settlement options. He has experience in contentious matters relating to patents protecting commercially important products. He also co-defended such patents in opposition and appeal procedures at the EPO, and provided crucial support for parallel national litigation in the US and pan-European enforcement and nullity actions.
Antoine Courgeon graduated from the University of Nice-Sophia Antipolis (FR) with an MSC in Biochemistry and Pharmacology. In his final year, he carried out a research project at the Institute Pasteur studying the expression of cannabinoid receptors in rat neuronal cells. He qualified as both a European Patent Attorney in 2002 and a French Patent Attorney in 2009.
Antoine Courgeon is a lecturer for the SPARK educational program of the Charité-Universitätsmedizin Berlin, a registered mentor of the Berlin Innovation Network for Advanced Material (INAM) and he also gave IP conferences on Biotechnology for the IP Forum Institute.